Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | CDC42 | P60953 | 1/20 | 0.36 |
| ▸ | RAC1 | P63000 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955030 | 1.00 | NR1H2 (0.46) | NR1H2ALDH1A1KDM4EL3MBTL1HPGD | |
| SCHEMBL29953334 | 0.90 | NR1H2 (0.45) | NR1H2ALDH1A1KDM4ECA12CA9 | |
| SCHEMBL513258 | 0.90 | NR1H2 (0.45) | NR1H2ALDH1A1KDM4ECA12CA9 | |
| SCHEMBL2562727 | 0.86 | KCNQ3 (0.41) | NR1H2KDM4ECA12CA9 | |
| SCHEMBL29764626 | 0.84 | CA12 (0.40) | NR1H2ATRATRIPCA12CA9 | |
| SCHEMBL1623033 | 0.84 | CA12 (0.40) | NR1H2ATRATRIPCA12CA9 | |
| SCHEMBL29957250 | 0.84 | NR1H2 (0.44) | NR1H2ATRATRIPCA12CA9 | |
| SCHEMBL17690271 | 0.84 | ESR2 (0.40) | NR1H2CA12CA9 | |
| SCHEMBL593975 | 0.84 | NR1H2 (0.44) | NR1H2ATRATRIPCA12CA9 | |
| SCHEMBL15332131 | 0.83 | NR1H2 (0.37) | NR1H2ATRATRIPCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636385-B2 | Selective ligands for tau aggregates | SENTONIX, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2024263753-A1 | SULFOXIMINE BASED STT3A/B MODULATORS FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-12097262-B2 | mTORC1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240066134-A1 | mTORC1 INHIBITORS | UNIV CALIFORNIA (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066134-A1 | mTORC1 INHIBITORS | UNIV CALIFORNIA (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066134-A1 | mTORC1 INHIBITORS | UNIV CALIFORNIA (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2023121238-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121238-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | disclosed |
| US-11452780-B2 | Mtorc1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-27 | — | — | US | disclosed |
| CN-113620978-A | mTORC1 inhibitors | 加利福尼亚大学董事会 | 2021-11-09 | — | — | CN | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097262-B2 | mTORC1 inhibitors | MTOR, RPTOR, RICTOR | NR1H2 3712/4885ALDH1A1 4715/4885KDM4E 1643/4885 |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NR1H2 3796/4885ALDH1A1 2583/4885KDM4E 980/4885 |
| US-20240066134-A1 | mTORC1 INHIBITORS | MTOR, RPTOR, RICTOR | NR1H2 3712/4885ALDH1A1 4715/4885KDM4E 1643/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | NR1H2 4098/4885ALDH1A1 939/4885KDM4E 709/4885 |
| US-12636385-B2 | Selective ligands for tau aggregates | MAPT, PSEN2, PSEN1 | NR1H2 678/4885ALDH1A1 4853/4885KDM4E 4519/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | NR1H2 2585/4885ALDH1A1 747/4885KDM4E 733/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NR1H2 3732/4885ALDH1A1 2459/4885KDM4E 1149/4885 |
| US-11452780-B2 | Mtorc1 inhibitors | MTOR, RPTOR, RICTOR | NR1H2 3712/4885ALDH1A1 4715/4885KDM4E 1643/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | NR1H2 1652/4885ALDH1A1 3053/4885KDM4E 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.